Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Assets Average (2018 - 2025)

VYNE Therapeutics' Assets Average history spans 8 years, with the latest figure at $37.4 million for Q4 2025.

  • For Q4 2025, Assets Average fell 47.68% year-over-year to $37.4 million; the TTM value through Dec 2025 reached $37.4 million, down 47.68%, while the annual FY2025 figure was $48.5 million, 41.03% down from the prior year.
  • Assets Average reached $37.4 million in Q4 2025 per VYNE's latest filing, down from $50.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $141.6 million in Q2 2021 to a low of $22.1 million in Q3 2023.
  • Average Assets Average over 5 years is $68.4 million, with a median of $61.7 million recorded in 2025.
  • Peak YoY movement for Assets Average: plummeted 57.79% in 2022, then surged 268.21% in 2024.
  • A 5-year view of Assets Average shows it stood at $74.2 million in 2021, then plummeted by 40.91% to $43.8 million in 2022, then soared by 33.41% to $58.5 million in 2023, then rose by 22.36% to $71.6 million in 2024, then crashed by 47.68% to $37.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Assets Average are $37.4 million (Q4 2025), $50.6 million (Q2 2025), and $61.7 million (Q1 2025).